Table 3. Adverse effects (at least 3%) in placebo-controlled studies of dapagliflozin1.
Adverse effects | Dapagliflozin 5 mg (n = 1,145) | Dapagliflozin 10 mg (n = 1,193) | Placebo (n = 1,393) |
Female genital mycotic infections | 8.4% | 6.9% | 1.5% |
Nasopharyngitis | 6.6% | 6.3% | 6.2% |
UTI | 5.7% | 4.3% | 3.7% |
Back pain | 3.1% | 4.2% | 3.2% |
Increased urination | 2.9% | 3.8% | 1.7% |
Note: UTI = urinary tract infection.